Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 9/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.39 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22944175 | 0.84 | EPHA2 (0.52) | EPHA2EPHB4ERBB2P2RX3P2RX2 | |
| SCHEMBL20241498 | 0.83 | EPHA2 (0.50) | EPHA2EPHB4ERBB2P2RX3P2RX2 | |
| SCHEMBL20242070 | 0.80 | EPHA2 (0.51) | EPHA2EPHB4ERBB2P2RX3P2RX2 | |
| SCHEMBL29827125 | 0.79 | EPHA2 (0.51) | EPHA2EPHB4ERBB2P2RX3P2RX2 | |
| SCHEMBL4510923 | 0.77 | EPHA2 (0.54) | EPHA2EPHB4ERBB2RETNR1H4 | |
| SCHEMBL12527146 | 0.76 | EPHA2 (0.47) | EPHA2EPHB4ERBB2P2RX3P2RX2 | |
| SCHEMBL15774857 | 0.76 | EPHA2 (0.47) | EPHA2EPHB4ERBB2P2RX3P2RX2 | |
| SCHEMBL19474638 | 0.76 | EPHA2 (0.49) | EPHA2EPHB4ERBB2P2RX3P2RX2 | |
| SCHEMBL13482008 | 0.76 | EPHA2 (0.51) | EPHA2EPHB4ERBB2BUB1NR1H4 | |
| SCHEMBL19474639 | 0.76 | EPHA2 (0.49) | EPHA2EPHB4ERBB2P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110337433-B | Compounds and pharmaceutical compositions for modulating SGK activity and methods thereof | 南京奥利墨斯医药科技有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-11236083-B2 | Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof | Orimos Therapeutics Co., Ltd. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-11236083-B2 | Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof | Orimos Therapeutics Co., Ltd. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20210032239-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING SGK ACTIVITY, AND METHODS THEREOF | Orimos Therapeutics Co., Ltd. (CN) | 2021-02-04 | — | — | US | disclosed |
| US-20210032239-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING SGK ACTIVITY, AND METHODS THEREOF | Orimos Therapeutics Co., Ltd. (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-3551613-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING SGK ACTIVITY, AND METHODS THEREOF | New Era Pharma, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018106459-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING SGK ACTIVITY, AND METHODS THEREOF | NEW ERA PHARMA, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236083-B2 | Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof | SGK1, SGK2, SGK3 | EPHA2 2523/4885EPHB4 3500/4885ERBB2 1928/4885 |
| US-20210032239-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING SGK ACTIVITY, AND METHODS THEREOF | SGK1, SGK2, SGK3 | EPHA2 1838/4885EPHB4 2869/4885ERBB2 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.